Evidence map›Paper›PMID 41786905›Full record

ArticleNPJ precision oncology2026

Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.

Allison L Hunt, Jamie Randall, Jonathan D Ogata, Laura Johnston, Whitney Swain, Savannah Melvin, Meenakshi Sharma, Valerie Calvert, G Larry Maxwell, Nicholas W Bateman and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Allison L HuntWomen's Health Integrated Research Center, Women's Service Line, Inova Health System, Annandale, VA, USA.
Jamie RandallInova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA.
Jonathan D OgataGynecologic Cancer Center of Excellence and the Women's Health Integrated Research Center, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.
Laura JohnstonInova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA.
Whitney SwainInova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA.
Savannah MelvinInova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA.
Meenakshi SharmaInova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA.
Valerie CalvertCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA.
G Larry MaxwellWomen's Health Integrated Research Center, Women's Service Line, Inova Health System, Annandale, VA, USA.
Nicholas W BatemanGynecologic Cancer Center of Excellence and the Women's Health Integrated Research Center, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.
Emanuel F Petricoin *Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. ePetrico@gmu.edu.
Thomas P Conrads *Women's Health Integrated Research Center, Women's Service Line, Inova Health System, Annandale, VA, USA. Conrads@whirc.org.
Timothy L Cannon *Inova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA. Timothy.Cannon@inova.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent successes of HER2-targeting agents, even in tumors characterized by FDA-approved molecular testing as HER2-negative or non-amplified, have underscored the limitations of current diagnostic approaches for accurately identifying patients with actionable HER2/EGFR activation/phosphorylation. We therefore performed a multi-omic investigation integrating clinical next-generation sequencing with a CLIA-certified reverse-phase protein array (RPPA) assay and laser microdissection-enriched tumor samples to characterize ERBB2/HER2 at the DNA, RNA, protein, and phosphoprotein level in patients with advanced pan-cancer solid tumor malignancies. Functional pathway activation mapping by RPPA revealed several patients with ERBB2 genomic or transcriptomic alterations and/or HER2

Identifiers

PMID41786905
PMCPMC13087044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.